Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
C-reactive protein, fibrinogen, and cardiovascular disease prediction.
Emerging Risk Factors Collaboration; Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Björkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D'Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engström G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jørgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J. Emerging Risk Factors Collaboration, et al. Among authors: tosetto a. N Engl J Med. 2012 Oct 4;367(14):1310-20. doi: 10.1056/NEJMoa1107477. N Engl J Med. 2012. PMID: 23034020 Free PMC article.
Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
von Drygalski A, Chowdary P, Kulkarni R, Susen S, Konkle BA, Oldenburg J, Matino D, Klamroth R, Weyand AC, Jimenez-Yuste V, Nogami K, Poloskey S, Winding B, Willemze A, Knobe K; XTEND-1 Trial Group. von Drygalski A, et al. N Engl J Med. 2023 Jan 26;388(4):310-318. doi: 10.1056/NEJMoa2209226. N Engl J Med. 2023. PMID: 36720133 Clinical Trial.
Can the Charlson comorbidity index help to guide DOAC dosing in patients with atrial fibrillation and improve the efficacy and safety of treatment? A subanalysis of the MAS study.
Palareti G, Legnani C, Testa S, Paoletti O, Cini M, Antonucci E, Pengo V, Poli D, Ageno W, Prandoni P, Prisco D, Tosetto A; MAS Working Group. Palareti G, et al. Among authors: tosetto a. Curr Probl Cardiol. 2025 Jan;50(1):102913. doi: 10.1016/j.cpcardiol.2024.102913. Epub 2024 Oct 30. Curr Probl Cardiol. 2025. PMID: 39481583
Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy.
Federici AB, Santoro RC, Santoro C, Pieri L, Santi RM, Barillari G, Borchiellini A, Tosetto A, Zanon E, De Cristofaro R, Mairal E, Mir R. Federici AB, et al. Among authors: tosetto a. Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241264541. doi: 10.1177/10760296241264541. Epub 2024 Jul 21. Clin Appl Thromb Hemost. 2024. PMID: 39033425 Free PMC article.
Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS).
Fischer K, Lassila R, Peyvandi F, Gatt A, Gouw SC, Hollingsworth R, Lambert T, Kaczmarek R, Carbonero D, Makris M; European HAemophilia Safety Surveillance (EUHASS) participants. Fischer K, et al. Res Pract Thromb Haemost. 2024 May 27;8(4):102461. doi: 10.1016/j.rpth.2024.102461. eCollection 2024 May. Res Pract Thromb Haemost. 2024. PMID: 39026659 Free PMC article.
Real-world experience of rIX-FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy - Results from IDEAL Part B.
Coppola A, Peyvandi F, Banov L, Cultrera D, Margaglione M, Tosetto A, Valdrè L, Schiavetti I, Loraschi A, Castaman G; Ideal Study Group. Coppola A, et al. Among authors: tosetto a. Haemophilia. 2024 Jul;30(4):1067-1070. doi: 10.1111/hae.15074. Epub 2024 Jun 20. Haemophilia. 2024. PMID: 39014893 Free article. No abstract available.
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.
Rocca B, Tosetto A, Petrucci G, Rossi E, Betti S, Soldati D, Iurlo A, Cattaneo D, Bucelli C, Dragani A, Di Ianni M, Ranalli P, Palandri F, Vianelli N, Beggiato E, Lanzarone G, Ruggeri M, Carli G, Elli EM, Renso R, Randi ML, Bertozzi I, Loscocco GG, Ricco A, Specchia G, Vannucchi AM, Rodeghiero F, De Stefano V, Patrono C; Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators. Rocca B, et al. Among authors: tosetto a. Am J Hematol. 2024 Aug;99(8):1462-1474. doi: 10.1002/ajh.27418. Epub 2024 Jun 15. Am J Hematol. 2024. PMID: 38877813 Free article. Clinical Trial.
252 results